These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36461742)

  • 1. Clinical Pharmacology Considerations on Recombinant Adeno-Associated Virus-Based Gene Therapy.
    Sun K; Liao MZ
    J Clin Pharmacol; 2022 Dec; 62 Suppl 2():S79-S94. PubMed ID: 36461742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PK/PD and Bioanalytical Considerations of AAV-Based Gene Therapies: an IQ Consortium Industry Position Paper.
    Kavita U; Sun K; Braun M; Lembke W; Mody H; Kamerud J; Yang TY; Braun IV; Fang X; Gao W; Gupta S; Hofer M; Liao MZ; Loo L; McBlane F; Menochet K; Stubenrauch KG; Upreti VV; Vigil A; Wiethoff CM; Xia CQ; Zhu X; Jawa V; Chemuturi N
    AAPS J; 2023 Jul; 25(5):78. PubMed ID: 37523051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene therapy using adeno-associated virus vectors.
    Daya S; Berns KI
    Clin Microbiol Rev; 2008 Oct; 21(4):583-93. PubMed ID: 18854481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vectrology of adeno-associated viruses (AAV).
    Skubis-Zegadło J; Stachurska A; Małecki M
    Med Wieku Rozwoj; 2013; 17(3):202-6. PubMed ID: 24296444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineering the AAV capsid to evade immune responses.
    Barnes C; Scheideler O; Schaffer D
    Curr Opin Biotechnol; 2019 Dec; 60():99-103. PubMed ID: 30807882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adeno-Associated Viral Vectors as a Tool for Large Gene Delivery to the Retina.
    Trapani I
    Genes (Basel); 2019 Apr; 10(4):. PubMed ID: 30970639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromosomal latency and expression at map unit 96 of a wild-type plus adeno-associated virus (AAV)/Neo vector and identification of p81, a new AAV transcriptional promoter.
    Hermonat PL; Santin AD; De Greve J; De Rijcke M; Bishop BM; Han L; Mane M; Kokorina N
    J Hum Virol; 1999; 2(6):359-68. PubMed ID: 10774553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera®).
    Salmon F; Grosios K; Petry H
    Expert Rev Clin Pharmacol; 2014 Jan; 7(1):53-65. PubMed ID: 24308784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current progress and limitations of AAV mediated delivery of protein therapeutic genes and the importance of developing quantitative pharmacokinetic/pharmacodynamic (PK/PD) models.
    Chowdhury EA; Meno-Tetang G; Chang HY; Wu S; Huang HW; Jamier T; Chandran J; Shah DK
    Adv Drug Deliv Rev; 2021 Mar; 170():214-237. PubMed ID: 33486008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The state of the art of adeno-associated virus-based vectors in gene therapy.
    Coura Rdos S; Nardi NB
    Virol J; 2007 Oct; 4():99. PubMed ID: 17939872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
    Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
    Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Adeno-associated Virus - A Safe and Promising Vehicle for Liverspecific Gene Therapy of Inherited and Non-inherited Disorders.
    Mak KY; Rajapaksha IG; Angus PW; Herath CB
    Curr Gene Ther; 2017; 17(1):4-16. PubMed ID: 28292253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adeno-associated virus (AAV) capsid engineering in liver-directed gene therapy.
    Rodríguez-Márquez E; Meumann N; Büning H
    Expert Opin Biol Ther; 2021 Jun; 21(6):749-766. PubMed ID: 33331201
    [No Abstract]   [Full Text] [Related]  

  • 14. The Perspective of DMPK on Recombinant Adeno-Associated Virus-Based Gene Therapy: Past Learning, Current Support, and Future Contribution.
    Chen N; Sun K; Chemuturi NV; Cho H; Xia CQ
    AAPS J; 2022 Jan; 24(1):31. PubMed ID: 35102450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adeno-associated virus (AAV)-based gene therapy products: What are toxicity studies in non-human primates showing us?
    Baldrick P; McIntosh B; Prasad M
    Regul Toxicol Pharmacol; 2023 Feb; 138():105332. PubMed ID: 36592683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of administration route on the biodistribution and shedding of replication-deficient AAV2: a qualitative modelling approach.
    Brandon EF; Hermsen HP; van Eijkeren JC; Tiesjema B
    Curr Gene Ther; 2010 Apr; 10(2):91-106. PubMed ID: 20222862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical study of rAAV2-sTRAIL: pharmaceutical efficacy, biodistribution and safety in animals.
    Ru Q; Li W; Wang X; Zhang S; Chen L; Zhang Y; Ge Y; Zu Y; Liu Y; Zheng D
    Cancer Gene Ther; 2017 Jun; 24(6):251-258. PubMed ID: 28429751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of risks related to the use of adeno-associated virus-based vectors.
    Tenenbaum L; Lehtonen E; Monahan PE
    Curr Gene Ther; 2003 Dec; 3(6):545-65. PubMed ID: 14683451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TFEB-mediated activation of the lysosome-autophagy system affects the transduction efficiency of adeno-associated virus 2.
    Popp L; Gomez E; Orji W; Ho M; Suh J; Segatori L
    Virology; 2017 Oct; 510():1-8. PubMed ID: 28688268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene therapy in skeletal muscle mediated by adeno-associated virus vectors.
    Qiao C; Koo T; Li J; Xiao X; Dickson JG
    Methods Mol Biol; 2011; 807():119-40. PubMed ID: 22034028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.